Topical administration of cyclosporin A in a solid lipid nanoparticle formulation

Pharmazie

Volumn 64, Issue 8, 2009, Pages 510-514

  Kim, Sung Tae ^a   Jang, Dong Jin ^b   Kim, Jong Hyo ^c   Park, Joo Yeon ^c   Lim, Ji Soo ^c   Lee, So Yeon ^c   Lee, Kyung Mi ^a   Lim, Soo Jeong ^d   Kim, Chong Kook ^b  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Science Academy   (South Korea)

^d Sejong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 4; INTERLEUKIN 5; SOLID LIPID NANOPARTICLE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG DIFFUSION; DRUG FORMULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SKIN PENETRATION; TH2 CELL; ANIMAL; CELL CULTURE; CHEMISTRY; ELECTROCHEMISTRY; HAIRLESS MOUSE; PARTICLE SIZE; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DERMATITIS, ATOPIC; ELECTROCHEMISTRY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; MICE; MICE, HAIRLESS; NANOPARTICLES; PARTICLE SIZE; SKIN ABSORPTION;

EID: 70349761874     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8373     Document Type: Article

References (32)

1. Arikan C, Kilic M, Tokat Y, Aydogdu S (2003) Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine A therapy. Transplant Proc 35: 3039-3041.
2. Bekerman T, Golenser J, Domb A (2004) Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci 93: 1264-1270.
3. Borgia SL, Regehly M, Sivaramakrishman R, Mehnert W, Korting HC, Danker K, Roder B, Kramer KD, Schäfer-Korting M (2005) Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 110: 151-163.
4. Brouwast JA, Honeywell-Nguyen PL (2002) Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 54 Suppl. 1: S41-S55.
5. Champman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, Linowski GJ, Jaracz E (2005) Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 53: S177-S185.
6. Cui Z, Mumper RJ (2001) Chitosan-based nanoparticles for topical immunization. J Control Release 75: 409-419.
7. Cui Z, Mumper RJ (2002) Topical immunization using nanoengineered genetic vaccines. J Controll Rel 81: 173-184.
8. Guo J, Ping Q (2000) Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 194: 201-207.
9. Karande P, Jain A, Mitrragotri (2004) Discovery of transdermal penetration enhancers by high-throughput screening. Nature Biotec 22: 192-197.
10. Kimura M, Obi M (2005) Ovalbumin-induced IL-4, IL-5 and IFN-g production in infants with atopic dermatitis. Int Arch Allergy Imm 137: 134-140.
11. Kohli AK, Alpar HO (2004) Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 275: 13-17.
12. Lee S, McAuliffe DJ, Kollias N, Flotte TJ, Doukas AG (2001) Permeabilization and recovery of the stratum corneum in vivo: The synergy of photomechanical waves and sodium lauryl sulfate. Lasers Med Surg 29: 145-150.
13. Lee SS, Tan AW (2004) Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study. Ann Acad Med Singapore 33: 311-313.
14. Leung D, Bogunuewicz M, Howell MD, Nomura I, Hamid QA (2004) New insights into atopic dermatitis. J Clin Invest 113: 651-657.
15. Lim SJ, Lee KM, Kim CK (2004) Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release 100: 53-61.
16. Magnusson BM, Anissumov YG, Cross SE, Robert MS (2004) Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 122: 993-999.
17. Mei Z, Chen H, When T, Yang Y, Yang X (2003) Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 56: 189-196.
18. Müller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of art. Eur J Pharm Biopharm 50: 161-177.
19. Müller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB (2006) Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317: 82-89.
20. Neslihan GR, Benit S (2004) Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58: 173-182.
21. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK (2005) Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol 152: 1173-1181.
22. Robson DC, Burton GG (2003) Cyclosporin: application in small animal dermatology. Vet Dermatol 14: 1-9.
23. Russell JJ (2002) Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician 66: 1899-1902.
24. Seong JH, Lee KM, Kim ST, Jin SE, Kim CK (2006) Polyethyleniminebased antisense oligonucleotides of IL-4 suppress the production of IL-4 in murine model of airway inflammation. J Gene Med 8: 314-323.
25. Song YK, Kim CK (2006) Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 27: 271-280.
26. Spergel JM, Brewer JP, Martin TR, Bhan AK, Geha RS (1998) Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101: 1614-1622.
27. Tatlipinar S, Akpek EK (2005) Topical cyclosporin in the treatment of ocular surface disorders. Br J Opthal 89: 1363-1367.
28. Ugazio E, Cavalli R, Gasco MR (2002) Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 241: 341-344.
29. Verma DD, Fahr A (2004) Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporine A. J Control Release 97: 55-56.
30. Wang S, Kara M (1998) Transdermal delivery of cyclosporin-A using electroporation. J Control Release 50(1-3): 61-70.
31. Wissing SA, Müller RH (2002) The influence of the crystallinity of lipid nanoparticles in their occlusive properties. Int J Pharm 242: 377-379.
32. Wissing SA, Müller RH (2003) Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 254: 65-68.